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Highlights 
 Mental health problems and other illicit drug use are associated with Butane Hash Oil (BHO) 
use. 
 BHO users were more likely to obtain their cannabis through prescription. 
 BHO is reported to have stronger negative effects than herbal cannabis. 
 
Abstract 
Background: Recent reports suggest an increase in use of extremely potent cannabis 
concentrates such as Butane Hash Oil (BHO) in some developed countries. The aims of this 
study were to examine the characteristics of BHO users and the effect profiles of BHO.  
Design: Anonymous online survey in over 20 countries in 2014 and 2015. Participants aged 18 
years or older were recruited through onward promotion and online social networks. The overall 
sample size was 181,870. In this sample, 46% (N = 83,867) reported using some form of 
cannabis in the past year, and 3% reported BHO use (n = 5,922). 
Measurements: Participants reported their use of 7 types of cannabis in the past 12 months, the 
source of their cannabis, reasons for use, use of other illegal substances, and lifetime diagnosis 
for depression, anxiety and psychosis. Participants were asked to rate subjective effects of BHO 
and high potency herbal cannabis. 
Findings: Participants who reported a lifetime diagnosis of depression (OR = 1.15, p = .003), 
anxiety (OR = 1.72, p < .001) a larger number of substance use (OR = 1.29, p < .001) were more 
likely to use BHO than only using high potency herbal cannabis. BHO users also reported 
stronger negative effects and less positive effects when using BHO than high potency herbal 
cannabis (p < .001)  
Conclusion: Mental health problems and other illicit drug use were associated with use of BHO. 
BHO was reported to have stronger negative and weaker positive effects than high potency 
herbal cannabis. 
Keywords: cannabis concentrate, potency, butane hash oil, THC, user characteristics, profile 
1 Introduction 
Cannabis is the most widely used illicit substance globally and this is particularly the case in developed countries. For 
example, the prevalence of past year cannabis use is 13%, 10% and 12% in the US (SAMHSA, 2014), Australia (AIHW, 2014) and 
Canada (Rotermann and Langlois, 2015) respectively. There is also evidence that cannabis use has spread to low- and middle-income 
countries, with a reported prevalence of 7.5% in African countries (UN Office on Drugs and Crime, 2015).  
Cannabis users often report relaxation, euphoria, increased sociability and sexual pleasure as the main positive effects (Green 
et al., 2003). These effects are largely attributable to delta-9-tetrahydrocannabinol (THC), the primary psychoactive constituent in 
cannabis, but they may also be modulated by cannabidiol (CBD) (Curran et al., 2016; Englund et al., 2017; Iversen, 2001). Cannabis 
potency is usually defined by THC content, which varies by preparation type (for example, resin, oil or herbal), strain of cannabis and 
method of cultivation. In 2008, the domestic UK market was dominated by high potency, indoor-grown varieties ( e.g., skunk, 
sensimilla) that contain the highest THC content (approximately 15%), followed by outdoor-grown herbal cannabis (9%) and 
hash/resin (5%) (Hardwick and King, 2008). Similar results were found for cannabis obtained from UK cannabis users in a naturalistic 
setting (Freeman et al., 2014), but recent monitoring data are lacking (Freeman and Swift, 2016). In the Netherlands, popular indoor 
grown herbal cannabis increased in THC content from 9% in 2000 to 20% in 2004 (Pijlman et al., 2005) before decreasing to 15% in 
2015 (Niesink et al., 2015). Data from drug enforcement agency seizures (ElSohly et al., 2016) indicated high potency herbal cannabis 
has become increasingly prevalent in the USA with the overall potency of illicit cannabis rising from 4% in 1995 to 12% in 2014. 
Based on the results of a single study, the Australian cannabis market is similarly dominated by high potency herbal cannabis 
containing approximately 15% THC (Swift et al., 2013). There is some evidence that use of high potency herbal cannabis ( e.g., 
skunk, sensimilla) is associated with greater harms (Hall and Degenhardt, 2015), including higher levels of dependence (Freeman and 
Winstock, 2015) and an increased risk of developing a psychosis (Di Forti et al., 2015).  
More efficient methods of hash/resin production have also been used to produce higher potency products (e.g., 30-40% THC in 
the United States and Netherlands) (ElSohly et al., 2016; Niesink et al., 2015). Recently, new refined cannabis products with 
unprecedentedly high THC content (cannabis concentrates) have received increased media coverage in the US (Cavazos-Rehg et al., 
2016; Daniulaityte et al., 2015; Stogner and Miller, 2015a, 2015b). Their production appears to have been driven by growth in the 
medicinal cannabis industry in the US, with the intention of allowing users to limit their exposure to smoked herbal products by using 
smaller doses of more potent cannabis extracts. Butane Hash Oil (BHO) is one example, commonly referred to as “earwax”, “dabs”, 
“butter” and “shatter”. It can be prepared through a process called blasting, which involves passing butane through a steel or glass tube 
packed with dried cannabis trimmings to dissolve the THC. The butane-THC solution is then filtered and BHO obtained by 
evaporating the butane (Stogner and Miller, 2015b). Alternative methods of extraction include different solvents (e.g., propane) or 
carbon dioxide extraction. These new methods can produce “cannabis concentrates” with THC content as high as 76% (Raber et al., 
2015). The maximum THC content achievable using these new extraction techniques exceeds more traditional methods (e.g., dry 
extraction to ‘kief’, water extraction to ‘bubble hash’) (Raber et al., 2015) and is considerably stronger than high potency herbal 
cannabis (e.g., 15%). Cannabis concentrate users often obtain a very high dosage of THC in a single hit through a process known as 
“dabbing”, in which they heat up the product with a blow torch and inhale the vapor via a bong or oil pipe. With e-cigarettes becoming 
more popular and accessible, a small but significant number of young people report using e-cigarettes to vaporize liquid hash oil 
(Morean et al., 2015). Additional concerns are that the solvent-based extraction methods ( e.g., BHO) pose a significant risk of 
explosion and associated injury or death during production (Crawford, 2016; Jensen, Bertelotti, et al., 2015). They also leave residual 
solvents in the final product (Raber et al., 2015). These concerns may be offset by using different extraction methods (e.g., carbon 
dioxide), but the prevalence of use of these respective methods is currently unclear. 
The high THC content in cannabis concentrates and the rapid ingestion of THC might be associated with higher level of 
dependence, stronger withdrawal and the swifter development of tolerance (Loflin and Earleywine, 2014). While the long-term effects 
of cannabis concentrates such as BHO use are largely unknown, a recent study suggests that their use may heighten short term harms 
and produce more extreme acute effects, such as fainting (Miller et al., 2016). Use of concentrates has also been associated with an 
increased incidence of orthostatic hypotension leading to falls and injuries and emergency department visits for burns from explosions 
caused by overheated elements in “vape pens” (Russo, 2016).  
There are other health risks associated with concentrates. A recent study found that up to 70% of pesticide residues may be 
recruited into the smoked product (Sullivan et al., 2013) even in concentrates produced industrially for markets in US states where use 
is legal (Russo, 2016). Along with the increased popularity of e-cigarettes and vaping devices, there is an emerging trend for young 
people to use these devices to vaporise cannabis concentrate (Morean et al., 2015). This might add extra health risk because data from 
e-cigarette research has shown that the solvents propylene glycol and glycerine, when overheated can produce formaldehyde, a known 
carcinogen (Jensen, Luo, et al., 2015). This finding has been confirmed in studies of thinning agents used by cannabis oil commercial 
producers in Colorado (Troutt and DiDonato, 2017). Users also described a qualitative difference between the effects of BHO and 
traditional herbal cannabis, with the high produced from BHO more like that achieved by using “harder” drugs (Miller et al., 2016). 
Despite public health concerns about the recent popularity of BHO and other high potency extracts, there is limited research on their 
effects. To date the few published studies have been limited by small sample sizes, and these have not yet adequately characterized 
users. The aims of this study were to examine the profile and characteristics of BHO users, and to compare the effect profiles of BHO 
and high potency herbal cannabis in a very large sample of drug users recruited in the Global Drug Survey (GDS) in 2015 and 2016. 
2 Methods 
2.1 Sample 
GDS is the largest annual survey of drug use in the world. It uses anonymous, encrypted online survey methods to provide 
rapid access to very large numbers of sentinel drug-using populations (Winstock et al., 2015). As such it is a useful tool for identifying 
new trends in drug use, drug-related harms and routes of administration (Barratt et al., 2017; Hindocha et al., 2016; Winstock et al., 
2011). Data from GDS 2015 and GDS 2016 were used for this study. The overall sample size after data cleaning was 181,870. Sixty 
three percent of the participants were males and the mean age was 29.01 (SD = 11.38; Median: 25). Among this sample, 46% (n = 
83,867) reported using some form of cannabis in the past year, and 3% reported BHO use (n = 5,922). 
2.2 Procedure 
GDS 2015 and GDS 2016 were launched in November 2014 and 2015 respectively through global media partners. Participants 
were recruited through onward promotion and online social networks on websites including The Guardian, Vice, Ziet-on-Line, 
Liberation, Fairfax Media in Australia and New Zealand and other international publications. The survey was translated into 10 
languages and has partners in over 20 countries. All participants confirmed that they were aged ≥16 years, and consented for the 
information they gave to be analysed. Ethical approval was received from the joint South London and Maudsley and Institute of 
Psychiatry, Psychology and Neuroscience National Health Service (NHS) Research Ethics Committee.  
2.3 Measures 
2.3.1 Cannabis use. Participants were shown pictures of seven forms of cannabis products, including indoor grown high 
potency herbal cannabis, resin/ hash, outdoor grown herbal weed/ bush/ pressed, edible cannabis, kief, oil and BHO. Self-reported 
measures of cannabis type have previously been validated against objective THC and CBD content (Freeman et al., 2014; van der Pol 
et al., 2013). Pictorial aids were used to improve their acceptability among an international sample with diverse cannabis terminology 
(Potter and Chatwin, 2012). Participants were asked to indicate which types of cannabis they had used in the last 12 months, and were 
then assigned to four cannabis user groups, 1) Non-user (NON), 2) Cannabis user – No high potency herbal cannabis and BHO use 
(CANN), 3) High potency herbal cannabis users with no BHO use (HI-POT), and 4) BHO users. These categories were mutually 
exclusive. Table 1 shows the types of cannabis used by the four groups. For participants who classified as CANN, 95% used normal 
weed and none used high potency herbal cannabis or BHO; for participants who were HI-POT, all of them used high potency herbal 
cannabis but no BHO use; BHO users tended to use a wide range of cannabis products. 
2.3.2 Source of cannabis was assessed using the items “How do you acquire your cannabis?” with the following response 
items: “I buy it”, “I grow it” and “I get it on prescription”. These responses were not mutually exclusive. For reasons of use, 
participants were asked to choose one of the following reasons “I use cannabis exclusively for recreational (pleasure) purposes”, “I use 
cannabis sometimes for medical reasons and most of the time for recreational purposes”, “I use cannabis most of the time for medical 
reasons and sometimes for recreational purposes” and “I use cannabis exclusively for medical reasons”. The subjective effects of BHO 
and high potency herbal cannabis were measured using 20 items on a 10-point scale (From 1 “Least” to 10 “Maximum”). Example 
items were “How strong would you rate this type of cannabis overall?” and “How would you rate its overall pleasurable effects?” 
Only data from participants who reported both BHO and high potency herbal cannabis use were included in the comparison of 
subjective effects. 
2.3.3 Other drug use. Participants were given a list of drugs, including MDMA, Cocaine, Amphetamine/ Methamphetamine, 
Heroin and LSD, and were asked to indicate if they had used each of them in the past 12 months. Mental Health. Participants were 
asked to indicate if they had received a diagnosis for depression, anxiety and/or psychosis in their lifetime. 
2.4 Analysis 
Comparisons of types of cannabis users and their demographic variables, mental health variables, other substance use 
variables, source of cannabis and reasons for use were performed using chi-square tests and ANOVAs. Two multinomial logistic 
regressions examined the adjusted associations between these variables and group membership. The reference groups in these two 
models were CANN and HI-POT respectively. Missing data were accounted for by multiple imputation. Five datasets were imputed to 
fill in missing values in the data (Rubin, 2009). Paired-sample t-tests were used to compare the subjective effects of high potency 
herbal cannabis and BHO in those participants who reported use of both types of cannabis. All analyses were done in STATA 13 
(StataCorp, 2013). 
3 Results 
Table 2 shows the demographic profiles of different types of cannabis users. BHO users were younger, more likely to be male, 
less likely to have attained a higher education, less likely to be heterosexual, and more likely to use cannabis daily/almost daily, than 
non-users and cannabis users who had not used high potency cannabis use or BHO (p < .001).  
Tables 3 shows the substance use, mental health and reason for use profiles of BHO users. They were more likely to use 
MDMA, cocaine, amphetamine/methamphetamine, heroin and LSD (p < .001) and were more likely to report a lifetime diagnosis of 
psychosis, depression and anxiety (p < .001). BHO users were more likely to have obtained their cannabis through prescription and to 
report using cannabis for medical purposes. Both high potency herbal cannabis users and BHO users were also more likely to report 
growing and purchasing their cannabis.  
Table 4 shows the results from multinomial logistic regressions. Compared to CANN, participants who were male, OR = 3.07, 
p < .001, transgender, OR = 2.14, p < 001, bisexual, OR = 1.19, p < .001, had lifetime diagnosis for depression, OR = 1.34, p < .001 
and anxiety, OR = 1.80, p < .001, and used a large number of substances, OR = 1.66, p < .001 were more likely to be BHO users. 
Having a higher level of education (p < .001) and being younger, OR = 0.99, p < .001 were associated with a lower likelihood of BHO 
use.  
Compared to HI-POT users (Last 2 columns in Table 4), participants who were older, OR = 1.01, p < .001, male, OR = 1.48, p 
< .001, bisexual, OR = 1.22, p < .001, had lifetime diagnosis of depression, OR = 1.15, p = .003 and anxiety, OR = 1.72, p < .001, and 
used a larger number of illicit substances, OR = 1.29, p < .001, were more likely to be BHO users. Having a higher level of education 
was associated with a lower likelihood of BHO use, p < .001.  
Table 5 shows the effect profiles of BHO and high potency herbal cannabis. Users of both types of cannabis generally reported 
that BHO was stronger than high potency herbal cannabis and they reported more negative and fewer positive effects when they used 
BHO. 
4 Discussion 
In the largest study to date, we found that BHO use was strongly associated with higher rates of self-reported anxiety and 
depression and other illicit drug use than high-potency herbal cannabis. BHO users were more likely to have a lower education level 
and to be bisexual. These results were generally consistent with previous research showing that users of more potent form of cannabis 
(higher level of THC) experienced higher level of harms, such as a stronger association between high potency cannabis and psychosis 
(Di Forti et al., 2015), and higher levels of cannabis dependence (Freeman and Winstock, 2015).  
We found a significant association between cannabis potency and mental health profiles. Participants with a lifetime diagnosis 
of depression were 1.18 more likely to use high-potency herbal cannabis and 1.34 more likely to use BHO. A similar pattern was 
found for anxiety. Although participants with a diagnosis of anxiety were no more likely to use high potency herbal cannabis, they 
were 1.80 times more likely to use BHO. BHO use was not associated with lifetime diagnosis of psychosis but this non-significant 
result should be interpreted with caution because the rate of psychosis in the sample was very low. Consistent with previous research 
(Di Forti et al., 2015), use of high-potency herbal cannabis was associated with a greater incidence of psychosis than use of less potent 
forms of cannabis and no cannabis use. 
Our study was cross-sectional and so causality cannot be inferred. It is possible that participants with a worse mental health 
profile may use BHO to self-medicate symptoms of depression and anxiety (Hall and Degenhardt, 2015). Our finding that BHO users 
were much more likely to report using cannabis for medical purposes and to obtain their cannabis via prescription was consistent with 
this self-medication hypothesis. However, the relationship between BHO use and poorer mental health may also be bidirectional. 
While using cannabis with high THC content may improve mood in the short term, it could exacerbate users’ symptom in long term 
(Hall and Degenhardt, 2015). It may also be that people who use cannabis to treat medical conditions are themselves more likely to 
report poorer mental health, given the association between chronic physical illness and poorer mental health (De Hert et al., 2011). 
Further research is needed to determine the incidence of adverse effects of BHO for medical use.  
A previous qualitative study found that BHO users were enthusiastic about its effects which they reported as positive and 
pleasurable (Miller et al., 2016). However, that study was limited by a small sample size (n=6) and only included people involved in 
treatment for drug-involved offences. By contrast, our large global dataset on participants who had experience with both BHO and 
high potency herbal cannabis showed that the effect profiles of BHO and high potency herbal were similar but BHO users generally 
reported more negative experiences, such as being more restless and anxious, and more forgetful when stoned. They also reported 
fewer positive experiences with BHO, such as feeling less pleasure and less relaxed. Interestingly, the largest difference we found was 
a lower ‘urge to use more when stoned’ for BHO than for high potency herbal cannabis. This finding is consistent with human and 
animal data suggesting that extremely high doses of THC are less reinforcing (and can be more aversive) than moderately high doses 
(Curran et al., 2016).  
There are several limitations in the current study. Firstly, our sample is a non-probability sample. However, the web-based 
method used in the GDS was an efficient way of gaining in-depth knowledge of drug use behaviours, and this is best suited to the 
comparison of use patterns and harms between population sub-segments. While this method allowed us to recruit a large sample who 
reported BHO use, this might limit the generalizability of our findings to the general population. However, it should be noted that 
prevalence of BHO use in the general population was low, and the cost of undertaking a general population survey to obtain a 
comparable sized sample would be prohibitively high. Our sample was from a sentinel drug-using population and provided important 
information about the characteristics of BHO users. Second, our study was based on cross-sectional self-reported survey, and 
therefore, causality cannot be inferred. In common with most online surveys, we were not able to assess the mental condition of the 
participants at the time of the survey, and we were not able to check if the participants gave consent under the influence of any 
substance. However, since the survey is completely anonymous and participants can withdraw from the study anytime by closing their 
web browser, there would be minimal risks to the participants. Thirdly, we focused on a single extraction technique (butane) and did 
not address alternative methods such as carbon dioxide (Raber et al., 2015). We selected BHO as it has been most frequently reported 
form in the literature to date, and we specifically asked users whether they had used this particular product. However it is possible that 
some users were unaware of the extraction technique used; some of our BHO sample may have used concentrates that were extracted 
using alternative methods. Nevertheless, our cannabis questions (seven different cannabis products, each depicted by text and image) 
is the most comprehensive we are aware of to date and it excluded alternatives such as traditional cannabis oil and dry extract (kief). 
Finally, we were unable to verify cannabinoid doses in BHO and other forms of cannabis. This is an important issue, because higher 
potency cannabis products could potentially reduce respiratory harms if users are able to adjust (titrate) the amount they use. There is 
some evidence for titration with traditional forms of cannabis, although this is not of sufficient magnitude to entirely offset the 
increased dose of THC received when using higher potency products (Freeman et al., 2014; van der Pol et al., 2013). 
5 Conclusion 
BHO is a form of refined cannabis product with a very high level of THC, the primary psychoactive ingredient in cannabis. 
This is the largest study of BHO users to date and the first to examine BHO user profiles. Although use was reportedly more common 
among those who used it for medical reasons, it was also associated with poorer mental health and greater use of other illicit 
substances. BHO was also reported to produce stronger negative and weaker positive effects than traditional high potency cannabis.  
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 Table 1. Types of cannabis used by different types of cannabis users. 
  
Non-user (N = 98,003) 
Cannabis user - No 
high potency herbal 
cannabis and BHO use 
(N = 25,371) 
High potency herbal 
cannabis users, no BHO 
use (N = 52,574) BHO users (N = 5,922) 
  N % N % N % N % 
High potency herbal cannabis - - 0 0 52574 100.00 5676 95.85 
Resin/ Hash - - 10278 40.51 32619 62.04 4485 75.73 
Normal weed - - 24129 95.10 45104 85.79 4619 78.00 
Edibles Group - - 4992 19.68 17870 33.99 4321 72.97 
Kief Group - - 1179 4.65 11735 22.32 4005 67.63 
Oil Group - - 692 2.73 4039 7.68 3720 62.82 
Butane hash oil - - 0 0 0 0 5922 100.00 
Table 2. Profiles of different cannabis users (Demographic). 
 
Non-user 
Cannabis user - No high 
potency herbal cannabis and 
BHO use 
High potency herbal cannabis 
users, no BHO use BHO users 
Demographic N % N % N % N % Chi-sq 
Gender 
         
  Female 41,401 42.96 9,924 39.69 12,880 24.91 1,127 19.49 5567*** 
  Male 54,576 56.63 14.962 59.84 38,582 74.63 4,618 79.85  
  Transgender 398 0.41 117 0.47 238 0.46 38 0.66  
Education 
         
  Below high school 12978 13.58 3280 13.29 9423 18.51 1467 26.21 4413*** 
  Finish high school 13091 13.70 4644 18.82 10778 21.17 1370 24.48  
  College certificate/ diploma 24454 25.58 6703 27.16 13995 27.49 1207 21.57  
  Undergraduate or above 45060 47.14 10049 40.72 16711 32.83 1553 27.75  
Sexual orientation 
        
  Bisexual 6458 6.91 2842 11.61 5510 10.90 796 14.18 1287*** 
  Heterosexual 81587 87.29 20099 82.10 42789 84.67 4630 82.49  
  Homosexual 5423 5.80 1540 5.29 2240 4.43 187 3.33  
Daily/ almost daily use (5 or more days a week) of any 
types of cannabis         
  No -  24065 94.85 46881 89.17 4737 79.99 1387*** 
  Yes -  1306 5.15 5693 10.83 1185 20.01  
 
M SD M SD M SD M SD F 
Age 31.30 12.29 27.61 10.75 25.80 8.87 25.68 9.43 3118*** 
***p < .001. 
Table 3. Profiles of different cannabis users (Past 12 months substance use and mental health). 
 
Non-user 
Cannabis user - No high 
potency herbal cannabis and 
BHO use 
High potency herbal 
cannabis users, no BHO 
use BHO users 
Past 12 months substance use N % N % N % N % Chi-sq 
MDMA use 12549 12.80 8308 32.75 24241 46.11 3071 51.86 22286*** 
Cocaine use 9101 9.29 5554 21.89 16001 30.44 2530 42.72 13114*** 
Amphetamine/Methamphetamine use 5570 5.68 3001 11.83 11446 21.77 1416 23.91 9390*** 
Heroin use 416 0.42 173 0.68 594 1.13 228 3.85 972*** 
LSD use 2528 2.58 3158 12.45 10844 20.63 2527 42.67 18937*** 
 M SD M SD M SD M SD F-statistics 
Number of substance use 0.31 0.77 0.80 1.07 1.20 1.24 1.65 1.35 11467*** 
Mental health N % N % N % N % Chi-sq 
Psychosis 688 0.71 170 0.68 541 1.04 57 1.50 83.59*** 
Depression 12539 12.96 3363 13.38 7250 13.96 1158 19.90 237.10*** 
Anxiety 7500 7.75 2183 8.69 4589 8.84 886 15.23 418.32*** 
Obtaining cannabis   N % N % N % Chi-sq 
Purchase   20512 80.85 48249 91.77 5296 89.50 1987*** 
Grow   1747 6.89 5611 10.67 1068 18.05 723*** 
Through prescription   205 0.81 535 1.02 425 7.18 1565*** 
Reason for using cannabis N % N % N % N % Chi-sq 
  Exclusively for recreational use   20588 84.12 37319 72.17 2425 41.67 4730*** 
  Sometimes for medical and mainly for recreational   3033 12.39 12171 23.54 2649 45.48  
  Mainly for medical but sometimes for recreational   690 2.82 2003 3.38 676 11.62  
  Exclusively for medical   164 0.67 220 0.43 72 1.24  
*** p < .001.
Table 4. Multinomial logistic regression (Ref: Cannabis user - No high potency herbal cannabis and BHO use) 
 
Ref: Cannabis user with no high potency cannabis and BHO use   
Ref: High potency herbal cannabis use, 
no BHO use 
 
Non-user 
High potency herbal cannabis 
users – no BHO use BHO users BHO users 
  OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
Age 1.02*** (1.02, 1.02) 0.98*** (0.98, 0.99) 0.99*** (0.99, 0.99) 1.01*** (1, 1.01) 
Gender (Ref: Female) 
    
  
  
  Male 0.80*** (0.77, 0.82) 2.08*** (2.01, 2.15) 3.07*** (2.85, 3.30) 1.48*** (1.38, 1.59) 
  Transgender 0.95 (0.76, 1.18) 1.55*** (1.24, 1.94) 2.14*** (1.44, 3.16) 1.38 (0.96, 1.98) 
Education level (Ref: Below high school) 
  
  
  
  Finished high school 0.78*** (0.74, 0.82) 0.80*** (0.76, 0.85) 0.66*** (0.60, 0.72) 0.82*** (0.76, 0.89) 
  College certificate/ diploma 0.97 (0.92, 1.02) 0.76*** (0.72, 0.80) 0.43*** (0.40, 0.47) 0.57*** (0.53, 0.62) 
  Undergraduate or above 1.03 (0.98, 1.08) 0.68*** (0.64, 0.71) 0.42*** (0.38, 0.48) 0.62*** (0.57, 0.67) 
Sexual orientation (Ref: Heterosexual) 
  
  
  
  Bisexual 0.63*** (0.60, 0.66) 0.96 (0.91, 1.01) 1.19*** (1.09, 1.30) 1.22*** (1.14, 1.35) 
  Homosexual 0.96 (0.91, 1.02) 0.61*** (0.57, 0.65) 0.41*** (0.35, 0.47) 0.67*** (0.57, 0.77) 
Number of substance use 0.59*** (0.58, 0.59) 1.30*** (1.28, 1.32) 1.66*** (1.63, 1.70) 1.29*** (1.25, 1.31) 
Psychosis 1.27** (1.06, 1.51) 1.28** (1.07, 1.53) 1.11 (0.85, 1.46) 0.89 (0.69, 1.09) 
Depression 1.00 (0.94, 1.05) 1.18*** (1.11, 1.25) 1.34*** (1.21, 1.48) 1.15** (1.03, 1.25) 
Anxiety 0.92** (0.86, 0.98) 1.05 (0.98, 1.12) 1.80*** (1.60, 2.01) 1.72*** (1.55, 1.91) 
***p < .001; **p < .01.
     1 
Table 5. Effect profiles of BHO and high potency cannabis (only participants who responded 
to both set of BHO and high potency cannabis questions were included). 
 BHO  High potency herbal 
cannabis 
  
 M SD M SD t Cohen's 
D 
N (Potential N 
= 5676) 
Urge to use more when 
stoned 
3.91 2.40 4.74 2.53 24.72*** 0.39 4014 
Taste 6.91 2.43 7.88 2.01 22.16*** 0.34 4291 
Overall pleasurable 
effect 
7.79 1.89 8.44 1.51 21.12*** 0.32 4422 
Increase appetite 5.95 2.43 6.64 2.21 21.27*** 0.33 4227 
Ability to talk 
comfortably 
6.64 2.48 7.13 2.24 16.39*** 0.25 4293 
Overall strength 8.49 1.57 8.00 1.43 16.41*** 0.25 4453 
Overall ability to 
function 
6.39 2.42 6.93 2.33 15.35*** 0.24 4226 
Preoccupied/ distracted 4.82 2.48 4.41 2.32 14.48*** 0.23 3939 
Forgetful when stoned 5.28 2.44 4.86 2.32 14.27*** 0.22 4173 
Restless/ Anxious 3.73 2.43 3.22 2.15 12.99*** 0.22 3558 
Purity 7.42 2.38 8.04 2.34 13.48*** 0.21 4075 
Harmful effect on 
lungs 
4.40 2.44 4.80 2.35 10.53*** 0.17 4023 
Worried about 
talking/looking at you 
3.26 2.48 2.95 2.23 10.57*** 0.18 3473 
Relaxed 7.59 2.10 7.94 1.74 10.57*** 0.15 4397 
Sedated/ sleepy 5.61 2.29 5.29 2.16 9.33*** 0.14 4224 
Thought racing 3.67 2.48 3.43 2.39 7.97*** 0.13 3575 
Hangover effect 2.65 2.15 2.42 2.03 7.52*** 0.13 3314 
Overall negative effect 2.95 2.04 2.74 1.95 6.69*** 0.11 3597 
Giggle/laugh 5.74 2.42 5.77 2.49 1.06 0.02 4092 
Sensory experience 
alteration 
5.91 2.44 5.92 2.45 0.36 0.01 4098 
***p <  
